Author/Authors :
Putlyaeva, L.V Engelhardt Institute of Molecular Biology - Russian Academy of Sciences, Russia , Schwartz, A.M Engelhardt Institute of Molecular Biology - Russian Academy of Sciences, Russia , Klepikova, A.V Institute for Information Transmission Problems (Kharkevich Institute) of the Russian Academy of Sciences, Russia , Vorontsov, I.E Vavilov Institute of General Genetics - Russian Academy of Sciences, Russia , Kulakovskiy, I.V Engelhardt Institute of Molecular Biology - Russian Academy of Sciences, Russia , Kuprash, D.V Engelhardt Institute of Molecular Biology - Russian Academy of Sciences, Russia
Abstract :
The SLAMF1 gene encodes CD150, a transmembrane glycoprotein expressed on the surface of T and B-lymphocytes, NK-cells, dendritic cells, and subpopulations of macrophages and basophils. We investigated the functional regulatory polymorphisms of the SLAMF1 locus associated with autoimmune processes, using bioin-formatics and a mutational analysis of the regulatory elements overlapping with polymorphic positions. In the reporter gene assay in MP-1 and Raji B-cell lines, the enhancer activity of the regulatory region of the locus con-taining the rs3753381 polymorphism demonstrated a twofold increase upon the introduction of the rs3753381 minor variant (G → A) associated with myasthenia gravis. An analysis of the nucleotide context in the vicinity of rs3753381 revealed that the minor version of this polymorphism improves several binding sites for the tran-scription factors of FOX and NFAT, and RXR nuclear receptors. All mutations that disrupt any of these sites lead to a decrease in the enhancer activity both in МР-1 and in Raji cells, and each of the two B-cell lines expresses a specific set of these factors. Thus, the minor variant of the rs3753381 polymorphism may contribute to the de-velopment of myasthenia gravis by modulating SLAMF1 expression, presumably in pathogenic B-lymphocytes.
Keywords :
transcriptional regulation , noncoding polymorphism , B cells , autoimmunity